ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 562

Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis

Uta Kiltz1, Robert B.M. Landewé 2, Désirée van der Heijde 3, Martin Rudwaleit 4, Michael Weisman 5, Nurullah Akkoç 6, Annelies Boonen 7, Jan Brandt-Jürgens 8, Philippe Carron 9, Maxime Dougados 10, Laure Gossec 11, Merryn Jongkees 12, Pedro Machado 13, Helena Marzo-Ortega 14, Anna Molto 15, Victoria Navarro-Compán 16, Karin Niedermann-Schneider 17, Percival Degrava Sampaio-Barros 18, Gleb Slobodin 19, Filip Van den Bosch 9, Astrid van Tubergen 20, Salima van weely 21, Dieter Wiek 22 and Jürgen Braun 23, 1Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 2Amsterdam University Medical Center, Amsterdam, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany, 5David Geffen School of Medicine at UCLA, Los Angeles, CA, 6Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, 7Maastricht University Medical Center, Maastricht, Netherlands, 8Rheumatologische Schwerpunktpraxis, Berlin, Germany, 9Ghent University Hospital, Ghent, Belgium, 1010Rheumatology B Department, Paris Descartes University, Cochin Hospital, Paris, France, 11Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 12seaynmedical, Netherlands, Netherlands, 13Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, United Kingdom, 14NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, 15Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, 16University Hospital La Paz, IdiPaz, Madrid, Spain, 17ZHAW Gesundheit Institut für Physiotherapie, Winterthur, Switzerland, 18Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil, 1918Department of Internal Medicine A, Bnai Zion Medical Center, Technion, Haifa, Israel, 20Maastricht University Medical Centre and Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands, 21Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, 22patient research partner, Germany, Germany, Germany, 23Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords:

Session Information

Date: Sunday, November 10, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: There is wide variation in the management of patients with axial spondyloarthritis (axSpA) worldwide with significant unmet needs such as delayed diagnosis. One way to achieve improvement in quality of care is to define quality standards (QS) in order to identify resources and processes which may need to be optimized.To develop ASAS QS to ultimately improve the quality of care for adults with axSpA.

Methods: The Assessment of SpondyloArthritis international Society (ASAS) QS group developed a step-wise approach starting with (I) open discussions resulting in a proposal for possible key areas for quality improvement. Thereafter, (II) ASAS members and invited patients discussed a provisional list with the possibility to propose additional key areas. (III) The complete list was then evaluated by ASAS members and invited patients. (IV) ASAS QS group prioritized key areas, and (V) phrased QS for the most important key areas. Finally (VI), a draft version was commented on, discussed and finally agreed by ASAS members.

Results: The ASAS QS group, consisting of 20 rheumatologists, 2 physiotherapists and 2 patients, provided 34 potentially key areas for quality improvement which were commented by 140 participants (86 physicians, 42 patients). Within that process 3 new key areas were proposed and all 37 key areas were again evaluated by 120 participants (86 physicians, 29 patients). 5 key areas were identified to be most important to phrase QS: referral, rheumatologic assessment, treatment, education/self-management and comorbidities. Altogether, 9 QS (table) were endorsed by ASAS.

Conclusion: ASAS successfully developed the first QS set for improvement of health care provided for adults with axSpA.


Table 1

Table: ASAS quality standards for patients with axial spondyloarthritis

Disclosure: U. Kiltz, AbbVie, 2, 5, 8, ABBVIE, NOVARTIS, CHUGAI, JANSEN, MSD, UCB, 8, ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB, 5, ABBVIE, NOVARTIS, PFIZER,BIOGEN, 2, Biocad, 2, 5, Biogen, 2, 5, Chugai, 2, 5, 8, Eli Lilly, 2, 5, Eli Lilly and Company, 5, Grünenthal, 2, 5, 8, Janssen, 8, Jasnssen, 2, 5, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; R. Landewé, Abbott, 2, 5, 8, Abbott, Amgen, Bristol-Myers Squibb, Centocor, Merck, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 8, Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 2, AbbVie, 5, Abbvie, 5, 8, AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Centocor, GSK, Novartis, Merck, Pfizer, Roche, Schering- Plough, UCB, Wyeth, 5, Ablynx, 5, Amgen, 2, 5, 8, AstraZeneca, 5, BMS, 5, 8, Bristol Myers Squibb, 5, 8, Bristol-Myers Squibb, 5, Celgene, 5, 8, Centocor, 2, 5, 8, Director of Rheumatology Consultancy BV, which is a registered company under Dutch law, 6, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Eli-Lilly, 5, 8, Galapagos, 5, 8, Gilead, 5, 8, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, 8, Janssen, 5, 8, Merck, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Rheumatology bv, 4, Rheumatology Consultancy BV, 9, Roche, 2, 5, 8, Schering-Plough, 2, 5, 8, UCB, 5, 8, UCB Pharma, 2, 5, 8, Wyeth, 2, 5, 8; D. van der Heijde, AbbVie, 5, AbbVie, Amgen, Astellas, AstraZeneca, BMS, 5, Amgen, 5, Astellas, 5, 9, Astellas Pharma, 5, AstraZeneca, 5, BMS, 5, Boehringer Ingelheim, 5, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb, 5, Celgene, 5, Daiichi, 5, 9, Daiichi Sankyo, 5, Director of Imaging Rheumatology, 6, Director of Imaging Rheumatology bv, 9, Eli Lilly, 5, Eli Lilly and Company, 5, Eli-Lilly, 5, Galapagos, 5, Gilead, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, GSK, 5, 8, Imaging Rheumatology bv, 9, Imaging Rheumatology BV, 9, Imaging Rheumatology bv., 9, Janssen, 5, 8, Janssen Pharmaceutica, 5, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Pfizer Inc, 5, Regeneron, 5, 8, Rheumatology bv, 4, 9, Roche, 5, 8, Sanofi, 5, 8, Takeda, 5, 8, Takeda Pharmaceutical Company, 5, UCB, 5, 8, UCB Pharma, 5; M. Rudwaleit, Abbott, 5, AbbVie, 5, 8, BMS, 5, 8, Bristol Myers-Squibb, 5, 8, Celgene, 5, 8, Chugai, 5, 8, Eli Lilly, 5, 8, Eli Lily, 5, 8, Janssen, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB Pharma, 5, 8; M. Weisman, AbbVie, 9, Boehringer Ingelheim, 9, Eli Lilly, 5, Lilly, 5, 9, Novartis, 5, Paul Hastings, 9, SetPoint Medical, 9, Takeda, 9, Tharpe & Howell LLP, 9, UCB, 5; N. Akkoç, None; A. Boonen, AbbVie, 2, Amgen, 2, Celgene, 2, Eli Lilly and Company, 5, Janssen, 8, Lilly, 5, 8, Novartis, 5, Sandoz, 5, 8, UCB, 5, 8; J. Brandt-Jürgens, AbbVie, 5, 8, Abbvie, 5, 8, BMS, 5, 8, Eli Lilly, 5, 8, Janssen, 5, 8, Lilly, 5, 8, Medac, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi-Aventis, 5, 8, UCB, 5, 8; P. Carron, None; M. Dougados, None; L. Gossec, Abbvie, 5, AbbVie, 5, Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, SAnofi-Aventis, UCB, 5, Amgen, 5, Biogen, 5, BMS, 2, 5, Celgene, 5, Celgene Corporation, 2, Janssen, 5, Lilly, 2, 5, MSD, 5, Nordic Pharma, 5, Novartis, 5, Pfizer, 2, 5, Sanofi, 5, Sanofi-Aventis, 5, UCB, 5; M. Jongkees, None; P. Machado, None; H. Marzo-Ortega, AbbVie, 5, 8, AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, 5, Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer, Ucb, 5, 8, AbbVie, Celgene, Janssen, Lilly, Novartis,Pfizer and UCB, 8, Celgene, 5, 8, Eli Lilly and Company, 5, 8, Janssen, 2, 5, 8, Janssen and Novartis, 2, Janssen, Novartis, 2, Novartis, 2, 5, 8, Pfizer, 5, 8, UCB, 5, 8; A. Molto, None; V. Navarro-Compán, AbbVie, 5, 8, Bristol, 8, Bristol, Roche, 8, Eli Lilly and Company, 5, 8, Eli Lilly, Novartis, Abbvie, UCB, MSD, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, Roche, 8, UCB, 5, 8; K. Niedermann-Schneider, None; P. Sampaio-Barros, None; G. Slobodin, None; F. Van den Bosch, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, Bristol-Myers Squibb, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB, 5, 8, ABBVIE, CELGENE, ELI LILLY, GALAPAGOS, MERCK, NOVARTIS, PFIZER, VCB, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Janssen, 5, 8, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Sanofi, 5, 8, UCB, 5, 8; A. van Tubergen, Abbvie, 2, Biogen, 2, Novartis, 2, 8, Pfizer, 2, UCB, 2; S. van weely, None; D. Wiek, None; J. Braun, Abbott, 2, 5, AbbVie, 2, 5, 6, 8, Amgen, 2, 5, 8, Baxter, 2, 5, 8, Biogen, 2, 8, 9, BMS, 2, 5, 8, Boehringer, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Celgene, 2, 3, 5, 8, Celltrion, 2, 5, 8, Centocor, 2, 5, 8, Chugai, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Hexal, 2, 5, 8, Janssen, 2, 5, 8, Johnson & Johnson, 2, 5, Medac, 2, 5, 8, MSD, 2, 5, MSD (Schering-Plough), 2, 5, 8, Mundipharma, 2, 5, 8, Mylan, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Pfizer (Wyeth, Hospira), 2, 5, 8, Roche, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, UCB Pharma, 2, 5, 8.

To cite this abstract in AMA style:

Kiltz U, Landewé R, van der Heijde D, Rudwaleit M, Weisman M, Akkoç N, Boonen A, Brandt-Jürgens J, Carron P, Dougados M, Gossec L, Jongkees M, Machado P, Marzo-Ortega H, Molto A, Navarro-Compán V, Niedermann-Schneider K, Sampaio-Barros P, Slobodin G, Van den Bosch F, van Tubergen A, van weely S, Wiek D, Braun J. Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/development-of-a-set-of-asas-quality-standards-for-adults-with-axial-spondyloarthritis/. Accessed August 12, 2022.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-set-of-asas-quality-standards-for-adults-with-axial-spondyloarthritis/